| 8/28/2020 | CVLM | PDL BioPharma offers to purchase 2.75% convertibles due 2021, 2024
|
| 12/16/2019 | CVLM | PDL BioPharma ups convertibles, stock buyback program to $275 million
|
| 12/13/2019 | CVLM | PDL BioPharma to exchange $119.3 million of 2021, 2024 convertibles
|
| 12/9/2019 | CVLM | PDL BioPharma board OKs repurchase program for convertibles, stock
|
| 9/13/2019 | CVLM | PDL BioPharma announces exchange of $86.1 million 2021 convertibles
|
| 4/16/2019 | CV | Market Commentary: Aphria on tap; Aqua America eyed; Western Digital convertibles in focus; PDL Biopharma active
|
| 1/29/2019 | CV | Market Commentary: NIO on tap; Square convertibles expand; Illumina active pre-earnings; Tesla in focus
|
| 1/29/2019 | CV | Market Commentary: Morning Commentary: Square convertibles active on analyst downgrade; PDL BioPharma eyed
|
| 2/16/2017 | CV | Market Commentary: OSI comes ‘aggressive’; secondary market seen cheaper; Molina expands on dollar-neutral basis
|
| 11/18/2016 | CV | Market Commentary: Salesforce.com convertibles slip from intraday highs, still firm; ON Semiconductor ticks up
|
| 11/17/2016 | CV | Market Commentary: PDL BioPharma prices, but market not impressed; AMD convertibles strengthen; Iconix unchanged
|
| 11/17/2016 | CV | Market Commentary: Morning Commentary: PDL BioPharma prices, but market not impressed; AMD convertibles strengthen
|
| 11/17/2016 | CV | New Issue: PDL BioPharma sells $150 million five-year convertible senior notes at 2.75%, up 25%
|
| 11/16/2016 | CV | Market Commentary: Weatherford, AMD gain; Endologix drops sharply; Medicines up; PDL BioPharma deal on tap
|
| 11/16/2016 | CV | Market Commentary: Morning Commentary: Weatherford gains; Medicines up after trial data; planned PDL BioPharma eyed
|
| 11/15/2016 | CV | Market Commentary: Peabody Energy, Chesapeake convertibles trade up outright; Priceline busy; Blucora firms
|
| 11/15/2016 | CV | PDL BioPharma to price $150 million five-year convertible senior notes via RBC
|
| 11/24/2015 | CVLM | PDL BioPharma buys back $53.6 million of 4% convertibles due 2018
|
| 3/4/2015 | CV | PDL BioPharma reduces conversion price on 3.75% convertibles due 2015
|
| 12/4/2014 | CV | PDL BioPharma adjusts conversion rates on 3.75%, 2.875% convertibles
|
| 11/19/2014 | BWCVLM | PDL BioPharma builds cash in anticipation of buying income-generating assets, says CEO
|
| 10/22/2014 | CVLM | PDL to issue shares, pay cash for $25.97 million 2.875% convertibles
|
| 9/18/2014 | CV | Market Commentary: PDL BioPharma drops after auditor news; Gilead remains weaker; secondary softness persists
|
| 9/18/2014 | CV | Market Commentary: Morning Commentary: PDL BioPharma 4% convertibles drop; two small, new deals in the market
|
| 9/4/2014 | CV | PDL BioPharma adjusts conversion rates on 3.75%, 2.875% convertibles
|
| 8/19/2014 | CV | Market Commentary: Salix surges on takeout rumors; Illumina paper trades actively; PDL BioPharma in line
|
| 8/19/2014 | CV | Market Commentary: Morning Commentary: Chesapeake Energy’s 2.5% convertibles come in; PDL BioPharma’s 4% bond in line
|
| 6/4/2014 | CV | PDL BioPharma adjusts conversion rates on 2.875%, 3.75% convertibles
|
| 3/4/2014 | CV | PDL BioPharma lifts conversion rates for 3.75%, 2.875% convertibles
|
| 2/7/2014 | CV | New Issue: PDL BioPharma prices $260.87 million four-year convertibles to yield 4%, up 15%
|
| 2/7/2014 | CV | Market Commentary: New PDL BioPharma trades up outright, mixed on hedge; existing PDL up with exchange offer
|
| 2/7/2014 | CVLM | PDL to issue shares, pay cash for $131.7 million 2.875% convertibles
|
| 2/7/2014 | CV | Market Commentary: Midday Commentary: PDL BioPharma trades at 102-103 outright; TTM Technologies retraces some gains
|
| 2/5/2014 | CV | PDL BioPharma plans $250 million four-year convertible to yield 3.75%-4.25%, up 12.5%-17.5%
|
| 12/20/2013 | CV | PDL BioPharma holders may convert 3.75%, 2.875% notes next quarter
|
| 12/4/2013 | CV | PDL BioPharma lifts conversion rates for 3.75%, 2.875% convertibles
|
| 9/27/2013 | CV | PDL BioPharma's 2.875% notes to be convertible during fourth quarter
|
| 9/4/2013 | CV | PDL BioPharma lowers conversion prices of 2.875% and 3.75% notes
|
| 6/20/2013 | CV | PDL BioPharma's 2.875% notes to be convertible during third quarter
|
| 6/3/2013 | CV | PDL BioPharma adjusts conversion rates of 2.875%, 3.75% convertibles
|
| 3/4/2013 | CV | PDL BioPharma adjusts conversion rates of 2.875%, 3.75% convertibles
|
| 1/10/2013 | CV | PDL must decide whether to wind down after patent expiration in 2014
|
| 12/5/2012 | CV | PDL BioPharma adjusts conversion rates on 2.875%, 3.75% convertibles
|
| 9/5/2012 | CV | PDL BioPharma adjusts conversion rates of 2.875%, 3.75% convertibles
|
| 6/5/2012 | CV | PDL BioPharma raises conversion rates on 2.875%, 3.75% convertibles
|
| 3/5/2012 | CV | PDL BioPharma adjusts conversion rates on 2.875%, 3.75% convertibles
|
| 2/13/2012 | CVLM | PDL BioPharma stockpiles cash, eyes purchase of revenue-generating assets as patents expire
|
| 2/2/2012 | CVLM | PDL BioPharma exchanges another $10.03 million of 2.875% convertibles
|
| 1/5/2012 | CVLM | PDL accepts $168.97 million of 2.875% convertibles for exchange
|
| 1/3/2012 | CVLM | PDL reveals preliminary results of 2.875% convertibles exchange offer
|
| 12/12/2011 | CV | PDL BioPharma corrects adjusted conversion rates for its convertibles
|
| 12/7/2011 | CV | PDL BioPharma adjusts conversion rates on 2.875%, 3.75% convertibles
|
| 11/15/2011 | CVLM | PDL BioPharma launches exchange offer for 2.875% convertible notes
|
| 9/7/2011 | CV | PDL adjusts conversion rates for 2.875% and 3.75% convertible notes
|
| 7/5/2011 | CVLM | PDL BioPharma redeems all $133.5 million 2% convertibles for cash
|
| 6/27/2011 | CV | PDL seeking new royalty assets; otherwise likely to wind-down in 2016
|
| 6/6/2011 | CV | PDL ups conversion rates for 2%, 2.875% and 3.75% convertibles
|
| 5/31/2011 | CV | Citigroup top U.S. market convertibles underwriter for year to date
|
| 5/24/2011 | CVLM | PDL BioPharma calls its outstanding 2% convertibles due 2012
|
| 5/16/2011 | CV | PDL BioPharma greenshoe lifts 3.75% convertibles to $155.25 million
|
| 5/13/2011 | CV | Market Commentary: Evergreen sinks on 'going concern' language; Kodak flat delta neutral on favorable ruling
|
| 5/11/2011 | CV | Market Commentary: PDL BioPharma up outright, flat on swap on debut; Rovi adds dollar neutral as stock surges
|
| 5/10/2011 | CV | New Issue: PDL BioPharma prices $135 million four-year convertibles to yield 3.75%, up 27.5%
|
| 5/10/2011 | CV | Market Commentary: Vishay Intertechnology moves up on debut; older PDL BioPharma unmoved with new deal ahead
|
| 5/9/2011 | CV | PDL BioPharma plans to price $135 million four-year convertible notes at 3.5%-4%, up 25%-30%
|
| 5/9/2011 | CV | Market Commentary: Tyson weakens; SunPower steady to lower; Vishay Intertechnology, PDL BioPharma on tap
|
| 5/9/2011 | CVLM | PDL BioPharma plans buyback of 2% convertibles with offering proceeds
|
| 3/8/2011 | CV | PDL BioPharma increases conversion rates for 2%, 2.875% convertibles
|
| 2/28/2011 | CV | Market Commentary: Thermo Fisher active, little changed on call; Medtronic, Medicis trade; primary picks up
|
| 11/5/2010 | CV | New Issue: PDL BioPharma issues $180 million new 2.875% five-year convertibles
|
| 10/27/2010 | CVLM | PDL BioPharma to retire 2% convertibles in swap for new 2.875% notes
|
| 9/16/2010 | CVLM | PDL BioPharma retires remaining $54.3 million 2.75% convertibles
|
| 9/13/2010 | CV | PDL BioPharma increases conversion rate on 2% convertibles due 2012
|
| 8/20/2010 | CVLM | PDL to go ahead with redemption of remaining 2.75% convertibles
|
| 8/13/2010 | CV | Market Commentary: PDL BioPharma falls 3 points outright; Qwest active on extended tender; Cephalon improves
|
| 8/5/2010 | CVLM | PDL to retire $61.6 million 2.75% convertibles; remainder called
|
| 7/1/2010 | CVLM | PDL buys back $84 million 2.75% convertible notes in second quarter
|
| 3/15/2010 | CV | PDL BioPharma adjusts conversion rates on 2%, 2.75% convertible notes
|
| 12/2/2009 | CV | PDL BioPharma increases conversion rates on 2012, 2023 convertibles
|
| 9/18/2009 | CV | PDL BioPharma raises conversion rates on 2% and 2.75% convertibles
|
| 9/14/2009 | CV | Market Commentary: PDL BioPharma, Human Genome in trade amid takeout talk; Magma finalizes exchange offer
|
| 7/31/2009 | CV | Market Commentary: Hologic gains ahead of results; buybacks lift PDL; Sybase eases; Mylan up on earnings
|
| 7/31/2009 | CV | PDL BioPharma paid $53.8 million to buy back $55 million convertibles
|
| 7/30/2009 | CV | PDL BioPharma buys $55 million 2% convertibles, 2.75% convertibles
|
| 7/27/2009 | CV | Market Commentary: Ford careens higher; Webster boosted by PIPE investment; Mylan mostly firm as shares drop
|
| 6/29/2009 | CV | Market Commentary: Convertibles strengthen; high yield in focus; LDK gains 1.5 points; School Specialty better
|
| 3/19/2009 | CV | PDL lifts conversion rate on 2.75% convertible notes due 2023
|
| 3/17/2009 | CV | PDL raises conversion rate on 2% convertible notes due 2012
|
| 1/6/2009 | CV | PDL BioPharma lifts conversion rate of 2% convertibles
|
| 12/22/2008 | CV | PDL ups conversion rate on 2.75%, 2% convertibles after spinoff of Facet
|
| 8/20/2008 | CV | Market Commentary: Fannie Mae slides again; Nabors up as oil adds; Newmont Mining extends gains on higher gold prices
|
| 8/19/2008 | CV | Market Commentary: Financials pummeled, Lehman, Wachovia hard hit; PDL BioPharma inks alliance with Bristol-Myers
|
| 5/6/2008 | CV | PDL lifts conversion rate to 61.426 shares on 2% convertibles due 2012
|
| 4/11/2008 | CV | Market Commentary: Virgin Media edges lower in debut; WaMu eases; Frontier Airlines sinks; but PDL BioPharma adds
|
| 4/10/2008 | CV | Market Commentary: Endo jumps on debut; takeout news lifts Millenium, other biotechs gain; NatCity in play
|
| 3/5/2008 | CV | Market Commentary: Convertibles mostly lower, but new issues move up; Ambac preferreds to price
|
| 9/5/2007 | CV | Market Commentary: Boston Properties, Best Buy, PDL BioPharma, Intel slip; JetBlue, Countrywide stand still; signs of life appear
|
| 8/30/2007 | CV | Market Commentary: Thornburg launches preferreds; Schering-Plough, other biotechs active; Sirius starts truckin'
|
| 5/24/2007 | CVSS | Probability of strategic action at PDL BioPharma high, Lehman report predicts
|
| 8/4/2006 | CV | Market Commentary: Scottish Re stays high; Reckson rides counter-bid rumors; Invitrogen shrugs off miss; PDL gains in line
|
| 5/3/2006 | CV | Market Commentary: Cephalon falls, PDL widens on results; NPS falls, MGI climbs on FDA news; XM firm despite lawsuits
|
